Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study.
Verboon C, Harbo T, Cornblath DR, Hughes RAC, van Doorn PA, Lunn MP, Gorson KC, Barroso F, Kuwabara S, Galassi G, Lehmann HC, Kusunoki S, Reisin RC, Binda D, Cavaletti G, Jacobs BC; IGOS consortium; GOS consortium. Verboon C, et al. Among authors: van doorn pa. J Neurol Neurosurg Psychiatry. 2021 Oct;92(10):1080-1088. doi: 10.1136/jnnp-2020-325815. Epub 2021 Jun 8. J Neurol Neurosurg Psychiatry. 2021. PMID: 34103340 Free PMC article.
Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.
Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn P, van Engelen B, van den Hoogen F, Hoogendijk J, Höweler C, de Jager A, Jennekens F, Koehler P, van der Leeuw H, de Visser M, Verschuuren JJ, Wintzen AR. Badrising UA, et al. Neurology. 2000 Nov 14;55(9):1385-7. doi: 10.1212/wnl.55.9.1385. Neurology. 2000. PMID: 11087787
Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.
Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, Breedveld FC, van Doorn PA, van Engelen BG, Hoogendijk JE, Höweler CJ, de Jager AE, Jennekens FG, Koehler PJ, de Visser M, Viddeleer A, Verschuuren JJ, Wintzen AR. Badrising UA, et al. Among authors: van doorn pa, van engelen bg. Ann Neurol. 2002 Mar;51(3):369-72. doi: 10.1002/ana.10121. Ann Neurol. 2002. PMID: 11891832 Clinical Trial.
Treatment of immune neuropathies.
Van Doorn PA, Garssen MP. Van Doorn PA, et al. Curr Opin Neurol. 2002 Oct;15(5):623-31. doi: 10.1097/00019052-200210000-00014. Curr Opin Neurol. 2002. PMID: 12352007 Review.
Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors.
van Sorge NM, van den Berg LH, Geleijns K, van Strijp JA, Jacobs BC, van Doorn PA, Wokke JH, van de Winkel JG, Leusen JH, van der Pol WL. van Sorge NM, et al. Among authors: van der pol wl, van strijp ja, van den berg lh, van doorn pa, van de winkel jg. Ann Neurol. 2003 May;53(5):570-9. doi: 10.1002/ana.10503. Ann Neurol. 2003. PMID: 12730990
Immunotherapy for Guillain-Barré syndrome.
van Doorn PA, van Koningsveld R. van Doorn PA, et al. Among authors: van koningsveld r. Lancet Neurol. 2004 Feb;3(2):84. doi: 10.1016/s1474-4422(03)00660-4. Lancet Neurol. 2004. PMID: 14746999 Review. No abstract available.
427 results